CareDx
CareDx Stock Rises Following American Society of Transplant Surgeons' Position Statement on Test Use
ASTS supports the use of dd-cfDNA as a biomarker of kidney transplant rejection, as well as peripheral blood gene expression profiling to help rule out heart transplant rejection.
MolDx Reimbursement Decision Likely to Have Negative Impact on CareDx, Natera Transplant Businesses
MolDx updated its guidance for rejection risk molecular testing with more restrictive language, potentially ending multimodal test coverage.
CareDx Q4, Full-Year Revenues Rise on Back of Cash Collections, Test Volumes
CareDx finished the three months ended Dec. 31 with $82.4 million in revenues compared to $79.2 million for the same quarter in 2021, narrowly beating analysts' average estimate of $81.7 million.
CareDx Preliminary Q4 Revenues up 4 Percent
The company says that strong test growth, cash collection, and guidelines inclusion helped drive fourth quarter revenues of $81.9 million to $82.2 million.
CareDx to Repurchase up to $50M of Common Stock
The company plans to purchase common shares through open market, privately negotiated, or other means for up to 24 months.